Abstract

Background: The assessment of prescription patterns is a critical step toward the rational use of drugs. Type II diabetes mellitus (T2DM) is a condition of insulin resistance and beta-cell dysfunction that often necessitates pharmacological intervention beyond lifestyle modifications. Teneligliptin, a DPP-4 inhibitor, has emerged as a promising therapy for managing uncontrolled T2DM. Methods: The Department of Pharmacology collaborated with the General Medicine department for conducting a cross-sectional study. A total of 570 patients were included in the study on the basis of predefined criteria including inclusion and exclusion criteria. The demographic details, as well as the prescription patterns, were reviewed and tabulated based on ADA guidelines. Results: Combination therapy was prescribed to 54% of patients, while 46% received monotherapy. Biguanides (40.58%) were the most commonly prescribed class, followed by sulfonylureas (32.8%) and DPP-4 inhibitors (18.71%). Teneligliptin was the most frequently prescribed DPP-4 inhibitor. Among combination therapies, Metformin+Teneligliptin (12.54%) and Metformin+Glimepiride (12.16%) were the most common. Triple-drug combinations featuring Metformin, Glimepiride, and Teneligliptin (9.6%) showed significant glycemic control. Physicians increasingly opted for newer agents such as Teneligliptin, not only as a monotherapy but also as a combination therapy. Conclusion: Teneligliptin, part of the rational prescribing practices in T2DM management, has increasingly gained momentum. Prescribing trends do have a lot of scope to optimize by closely adhering to essential drug lists and brand-neutral prescribing practices.